ConductScience.org, home

Paper20437015

Advanced-stage III/IV follicular lymphoma: treatment strategies for individual patients.

Heinzelmann F and 5 others. Strahlenther Onkol, 2010. Cited by 10 papers, by iCite.

Cite this record

ConductScience Library. Advanced-stage III/IV follicular lymphoma: treatment strategies for individual patients. Papers, record 20437015. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20437015

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Advanced-stage III/IV follicular lymphoma: treatment strategies for individual patients.
PubMed
Journal
Strahlenther Onkol
PubMed
Year
2010
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
10
iCite
Relative citation ratio, by iCite
0.2
iCite
Revised in PubMed
2026-10-28
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Heinzelmann FFrank
2Ottinger HHellmut
3Engelhard MMarianne
4Soekler MMartin
5Bamberg MMichael
6Weinmann MMartin

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Lymphoma, FollicularMajor topic
Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Combined Modality Therapy
Humans
Neoplasm Staging
Radioimmunotherapy
Rituximab
Survival Rate

Source PubMed

Download CSV of topics

References86

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
112652459First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma.Semin Oncol2003https://conductscience.org/library/papers/12652459PubMed
212969983BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients.Blood2004https://conductscience.org/library/papers/12969983PubMed
315453924Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.Clin Lymphoma2004https://conductscience.org/library/papers/15453924PubMed
410717153Radiobiological and Clinical Bases for Total Body Irradiation in the Leukemias and Lymphomas.Semin Radiat Oncol1995https://conductscience.org/library/papers/10717153PubMed
516230674New treatment options have changed the survival of patients with follicular lymphoma.J Clin Oncol2005https://conductscience.org/library/papers/16230674PubMed
616732818Value of low-dose 2 x 2 Gy palliative radiotherapy in advanced low-grade non-Hodgkin's lymphoma.Australas Radiol2006https://conductscience.org/library/papers/16732818PubMed
712663713Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma.J Clin Oncol2003https://conductscience.org/library/papers/12663713PubMed
816123223
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.
Blood2005https://conductscience.org/library/papers/16123223PubMed
99060552
Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte.
J Clin Oncol1997https://conductscience.org/library/papers/9060552PubMed
1012036859Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.Blood2002https://conductscience.org/library/papers/12036859PubMed
1115925981Analysis of local control in patients with non-Hodgkin's lymphoma according to the WHO classification.Strahlenther Onkol2005https://conductscience.org/library/papers/15925981PubMed
1217488686
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
Haematologica2007https://conductscience.org/library/papers/17488686PubMed
1311516864A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment.Int J Radiat Oncol Biol Phys2001https://conductscience.org/library/papers/11516864PubMed
1415684317Meta-analysis to evaluate the role of interferon in follicular lymphoma.J Clin Oncol2005https://conductscience.org/library/papers/15684317PubMed
158201380Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma.J Clin Oncol1994https://conductscience.org/library/papers/8201380PubMed
1615592494
Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications.
Bone Marrow Transplant2005https://conductscience.org/library/papers/15592494PubMed
178049425Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma.Blood1994https://conductscience.org/library/papers/8049425PubMed
1812702528Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma.Ann Oncol2003https://conductscience.org/library/papers/12702528PubMed
1918559872Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.J Clin Oncol2008https://conductscience.org/library/papers/18559872PubMed
2016873669
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.
Blood2006https://conductscience.org/library/papers/16873669PubMed

See all 86 referencesDownload CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.

PMIDTitleJournalYearIn PapersSource
37711166A rare case of follicular lymphoma of the bladder.Urol Case Rep2023https://conductscience.org/library/papers/37711166PubMed
28816963Efficacy and safety evaluation of fludarabine-based chemotherapy regimen for patients with non-Hodgkin lymphoma: A meta-analysis.Medicine (Baltimore)2017https://conductscience.org/library/papers/28816963PubMed
22430608Comparison on therapeutic effects of RFT and RCTVP regimen in the treatment of patients with indolent B-cell lymphoma in China.Med Oncol2012https://conductscience.org/library/papers/22430608PubMed
22349634Radiotherapy in stage I-III follicular non-Hodgkin lymphoma. Retrospective analysis of a series of 50 patients.Strahlenther Onkol2012https://conductscience.org/library/papers/22349634PubMed
21603989Interobserver variability of clinical target volume delineation in supra-diaphragmatic Hodgkin's disease: a multi-institutional experience.Strahlenther Onkol2011https://conductscience.org/library/papers/21603989PubMed
21544528Feasibility and toxicity of concomitant radio/immunotherapy with MabThera (Rituximab®) for patients with non-Hodkin's Lymphoma: results of a prospective phase I/II study.Strahlenther Onkol2011https://conductscience.org/library/papers/21544528PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20437015

GET https://conductscience.org/api/papers/v1/20437015/references?page=2